BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology 2016;27:1279-87. [DOI: 10.1016/j.jvir.2016.01.135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, Ayuso C. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology. 2011;54:2238-2244. [PMID: 21932394 DOI: 10.1002/hep.24670] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 7.8] [Reference Citation Analysis]
4 Gaba RC. Chemoembolization Practice Patterns and Technical Methods Among Interventional Radiologists: Results of an Online Survey. American Journal of Roentgenology 2012;198:692-9. [DOI: 10.2214/ajr.11.7066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
5 Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int 2014;34:612-20. [DOI: 10.1111/liv.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
6 Kulik L. Is radioembolization ready for the barcelona clinic liver cancer staging system? Hepatology 2010;52:1528-30. [DOI: 10.1002/hep.24030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Delumeau S, Lebigot J, Ridereau-zins C, Bouvier A, Boursier J, Aubé C. Aspects et évaluation post-thérapeutiques des lésions du foie après traitement non chirurgical. Journal de Radiologie 2011;92:632-58. [DOI: 10.1016/j.jradio.2011.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Shim JH, Lee HC, Won HJ, Shin YM, Kim KM, Lim YS, Suh DJ. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol. 2012;56:406-411. [PMID: 21782761 DOI: 10.1016/j.jhep.2011.04.028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
9 Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
10 Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, Kulik L, Desai K, Thornburg B, Mouli S, Hickey R, Miller FH, Yaghmai V, Ganger D, Lewandowski RJ, Salem R. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses: Riaz et al. Hepatology 2018;67:873-83. [DOI: 10.1002/hep.29480] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
11 Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, Valji K, Harris WP, Hippe DS, Kogut MJ. Safety and Efficacy of Drug-eluting Bead Chemoembolization for Hepatocellular Carcinoma: Comparison of Small-versus Medium-size Particles. Journal of Vascular and Interventional Radiology 2013;24:301-6. [DOI: 10.1016/j.jvir.2012.11.023] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 6.2] [Reference Citation Analysis]
12 Chekunov DA, Polyakov RS, Bagment NN, Moysyuk YG, Fedorov DN, Skipenko OG. [Transarterial therapy for hepatocellular cancer]. Khirurgiia (Mosk) 2015;:43-9. [PMID: 26762077 DOI: 10.17116/hirurgia2015943-49] [Reference Citation Analysis]
13 Zurera L, Espejo J, Lombardo S, Marchal T, Muñoz M, Canis M, Montero J. Histologic study of the effects of chemoembolization with preloaded doxorubicin beads in patients with hepatocellular carcinoma. Radiología (English Edition) 2015;57:419-27. [DOI: 10.1016/j.rxeng.2015.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826-834. [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
15 Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol 2022. [PMID: 35381853 DOI: 10.1007/s00330-022-08716-4] [Reference Citation Analysis]
16 Donahue LA, Kulik L, Baker T, Ganger DR, Gupta R, Memon K, Abecassis MM, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013;24:74-80. [PMID: 23273699 DOI: 10.1016/j.jvir.2012.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
17 He LN, Chen T, Fu S, Chen C, Jiang Y, Zhang X, Du W, Li H, Wang Y, Ali WAS, Zhou Y, Lin Z, Yang Y, Huang Y, Zhao H, Fang W, Zhang L, Hong S. Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy. Lung Cancer 2021;165:10-7. [PMID: 35051754 DOI: 10.1016/j.lungcan.2021.12.015] [Reference Citation Analysis]
18 Wang CY, Xia JG, Yang ZQ, Zhou WZ, Chen WH, Qi CJ, Gu JP, Wang Q. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 2020;10:4434. [PMID: 32157110 DOI: 10.1038/s41598-020-61209-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Minocha J, Lewandowski RJ. Assessing Imaging Response to Therapy. Radiologic Clinics of North America 2015;53:1077-88. [DOI: 10.1016/j.rcl.2015.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
20 Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, Pracht M, Raoul JL, Clément B, Garin E. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518-2525. [PMID: 23494107 DOI: 10.1245/s10434-013-2906-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
21 Riaz A, Salem R. Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. J Vasc Interv Radiol 2019;30:1893-4. [PMID: 31757337 DOI: 10.1016/j.jvir.2019.09.003] [Reference Citation Analysis]
22 Rezai P, Pisaneschi MJ, Feng C, Yaghmai V. A radiologist's guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers. AJR Am J Roentgenol 2013;201:237-45. [PMID: 23883205 DOI: 10.2214/AJR.12.9862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
23 Zurera LJ, Espejo JJ, Lombardo S, Marchal T, Muñoz MC, Canis M, Montero JL. Histologic study of the effects of chemoembolization with preloaded doxorubicin beads in patients with hepatocellular carcinoma. Radiologia 2015;57:419-27. [PMID: 25535030 DOI: 10.1016/j.rx.2014.07.008] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Bock B, Hasdemir D, Wandrer F, Rodt T, Manns MP, Schulze-Osthoff K, Bantel H. Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. Aliment Pharmacol Ther 2016;44:747-54. [PMID: 27485159 DOI: 10.1111/apt.13758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3059-3068 [PMID: 24696594 DOI: 10.3748/wjg.v20.i12.3059] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
26 Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol 2011;197:18-27. [PMID: 21701006 DOI: 10.2214/AJR.11.6581] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
27 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
28 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
29 Cousin S, Taieb S, Penel N. A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. Curr Opin Oncol 2012;24:338-44. [PMID: 22418613 DOI: 10.1097/CCO.0b013e3283528b73] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
30 Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim M. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014;34:305-12. [DOI: 10.1111/liv.12270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
31 Vouche M, Salem R, Lewandowski RJ, Miller FH. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? Abdom Imaging 2015;40:1471-80. [DOI: 10.1007/s00261-014-0295-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
32 Salem R, Miller FH, Yaghmai V, Lewandowski RJ. Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments. Journal of Hepatology 2013;58:1260-2. [DOI: 10.1016/j.jhep.2013.01.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
33 Steiner K, Papadopoulou A, Yu D. The role of interventional radiology in the treatment of hepatocellular carcinoma. Semin Ultrasound CT MR 2013;34:89-101. [PMID: 23395321 DOI: 10.1053/j.sult.2012.11.008] [Reference Citation Analysis]
34 Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
35 Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
36 Kim H, Chung JW, Choi SH, Im S, Yamasaki Y, Jun S, Jae HJ, Park JH. Augmentation of Chemotherapeutic Infusion Effect by TSU-68, an Oral Targeted Antiangiogenic Agent, in a Rabbit VX2 Liver Tumor Model. Cardiovasc Intervent Radiol 2012;35:168-75. [DOI: 10.1007/s00270-010-0081-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Cervera Deval J. [RECIST and the radiologist]. Radiologia 2014;56:193-205. [PMID: 22902252 DOI: 10.1016/j.rx.2012.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2012;35:1094-1101. [PMID: 22069121 DOI: 10.1007/s00270-011-0292-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
39 Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, Vaidya S, Monsky WL, Park JO, Bhattacharya R, Hippe DS, Harris WP. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score–Matched Study. Journal of Vascular and Interventional Radiology 2017;28:777-785.e1. [DOI: 10.1016/j.jvir.2017.02.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
40 Senthilnathan S, Memon K, Lewandowski RJ, Kulik L, Mulcahy MF, Riaz A, Miller FH, Yaghmai V, Nikolaidis P, Wang E. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology. 2012;55:1432-1442. [PMID: 22109811 DOI: 10.1002/hep.24812] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
41 Panebianco V, Barchetti F, Manenti G, Aversa T, Catalano C, Simonetti G. MR imaging-guided prostate biopsy: technical features and preliminary results. Radiol med 2015;120:571-8. [DOI: 10.1007/s11547-014-0490-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
42 Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012;264:285-294. [PMID: 22627601 DOI: 10.1148/radiol.12112142] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
43 Galizia MS, Töre HG, Chalian H, McCarthy R, Salem R, Yaghmai V. MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. Acad Radiol. 2012;19:48-54. [PMID: 22054801 DOI: 10.1016/j.acra.2011.09.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
44 Memon K, Kulik L, Lewandowski RJ, Gupta R, Ryu RK, Miller FH, Vouche M, Atassi R, Ganger D, Mulcahy MF, Salem R. Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology 2013;24:1189-1197.e2. [DOI: 10.1016/j.jvir.2012.12.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
45 Ye Z, Wang S, Chen W, Zhang X, Chen J, Jiang J, Wang M, Zhang L, Xuan Z. Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer. Oncol Lett 2020;20:1409-17. [PMID: 32724383 DOI: 10.3892/ol.2020.11673] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga. Hepatol Commun 2021. [PMID: 34783177 DOI: 10.1002/hep4.1861] [Reference Citation Analysis]
47 Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul J. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma: mRECIST Impact in Sorafenib-Treated HCC. Cancer 2012;118:147-56. [DOI: 10.1002/cncr.26255] [Cited by in Crossref: 191] [Cited by in F6Publishing: 174] [Article Influence: 17.4] [Reference Citation Analysis]
48 Yu JI, Park HC, Lim DH, Choi Y, Jung SH, Paik SW, Kim SH, Jeong WK, Kim YK. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89:814-821. [PMID: 24969795 DOI: 10.1016/j.ijrobp.2014.03.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
49 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55:1309-1316. [PMID: 21703196 DOI: 10.1016/j.jhep.2011.03.007] [Cited by in Crossref: 224] [Cited by in F6Publishing: 211] [Article Influence: 20.4] [Reference Citation Analysis]
51 Gordon AC, Gradishar WJ, Kaklamani VG, Thuluvath AJ, Ryu RK, Sato KT, Gates VL, Salem R, Lewandowski RJ. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014;25:1523-1532, 1532.e1-1532.e2. [PMID: 25156827 DOI: 10.1016/j.jvir.2014.07.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
52 Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transpl 2020;26:203-14. [PMID: 31677319 DOI: 10.1002/lt.25673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
53 Dinorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Annals of Surgery 2020;271:616-24. [DOI: 10.1097/sla.0000000000003253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
54 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 12.1] [Reference Citation Analysis]
55 Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, Gerken G, Yang D, Schlaak JF. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncol Lett 2013;6:1707-12. [PMID: 24260066 DOI: 10.3892/ol.2013.1612] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
56 Elsaid NAE, Kaddah RO, Fattah MSA, Salama NM. Subtraction MRI versus diffusion weighted imaging: Which is more accurate in assessment of hepatocellular carcinoma after Trans Arterial Chemoembolization (TACE)? The Egyptian Journal of Radiology and Nuclear Medicine 2016;47:1251-64. [DOI: 10.1016/j.ejrnm.2016.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. Abdom Imaging. 2011;36:300-314. [PMID: 21279353 DOI: 10.1007/s00261-011-9683-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
58 Wu Z, Xie Y, Xiong S, Li J, Sun X, Shi Q, Dan W, Jiang L. The Venous Occlusion Image Score: A Novel Quantitative Scoring Instrument for Cerebral Venous Sinus Thrombosis. J Stroke Cerebrovasc Dis 2021;30:105845. [PMID: 33964546 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105845] [Reference Citation Analysis]
59 Gordon AC, Gupta AN, Gabr A, Thornburg BG, Kulik LM, Ganger DR, Maddur H, Flamm SL, Boike JR, Moore CM, Borja-Cacho D, Christopher DA, Katariya NN, Ladner DP, Caicedo-Ramirez JC, Riaz A, Salem R, Lewandowski RJ. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol 2021;32:211-9. [PMID: 33349507 DOI: 10.1016/j.jvir.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2012;23:927-36. [PMID: 22633621 DOI: 10.1016/j.jvir.2012.04.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
61 Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73-80. [PMID: 23000237 DOI: 10.1016/j.jhep.2012.09.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 7.9] [Reference Citation Analysis]
62 Rajyaguru DJ, Borgert AJ, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al. J Clin Oncol 2018;36:2567-9. [PMID: 29945519 DOI: 10.1200/JCO.2018.78.6418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Reiner CS, Morsbach F, Sah BR, Puippe G, Schaefer N, Pfammatter T, Alkadhi H. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. J Vasc Interv Radiol. 2014;25:747-759. [PMID: 24630751 DOI: 10.1016/j.jvir.2014.01.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
64 Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, Caicedo JC, Abecassis M, Katariya N, Maddur H, Kulik L, Lewandowski RJ, Salem R. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging 2017;44:2195-202. [DOI: 10.1007/s00259-017-3792-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
65 Choi SJ, Kim J, Kim HS, Park H. Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Abdom Radiol (NY) 2017;42:1871-9. [PMID: 28204855 DOI: 10.1007/s00261-017-1082-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
66 Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R. Yttrium-90 radioembolization in the management of liver malignancies. Semin Oncol. 2010;37:94-101. [PMID: 20494701 DOI: 10.1053/j.seminoncol.2010.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
67 Shah RP, Brown KT, Sofocleous CT. Arterially directed therapies for hepatocellular carcinoma. AJR Am J Roentgenol. 2011;197:W590-W602. [PMID: 21940531 DOI: 10.2214/ajr.11.7554] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
68 Firl DJ, Kimura S, Mcvey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 2018;68:1448-58. [DOI: 10.1002/hep.29907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
69 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]
70 Liu G, Ouyang Q, Xia F, Fan G, Yu J, Zhang C, Wang D. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. HPB (Oxford). 2019;21:107-113. [PMID: 30017783 DOI: 10.1016/j.hpb.2018.06.1800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
71 Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015;25:380-390. [PMID: 25226843 DOI: 10.1007/s00330-014-3412-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
72 Wang D, Gaba RC, Jin B, Riaz A, Lewandowski RJ, Ryu RK, Sato KT, Ragin AB, Kulik LM, Mulcahy MF, Salem R, Larson AC, Omary RA. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011;18:828-36. [PMID: 21669349 DOI: 10.1016/j.acra.2011.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
73 Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Gates VL, Atassi B, Newman S, Omary RA, Benson AB 3rd, Salem R. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012;83:887-94. [PMID: 22137020 DOI: 10.1016/j.ijrobp.2011.07.041] [Cited by in Crossref: 103] [Cited by in F6Publishing: 80] [Article Influence: 9.4] [Reference Citation Analysis]
74 Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston M, Bekaii-Saab T. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer 2012;11:195-9. [PMID: 22277350 DOI: 10.1016/j.clcc.2011.12.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
75 Padia SA, Chewning RH, Kogut MJ, Ingraham CR, Johnson GE, Bhattacharya R, Kwan SW, Monsky WL, Vaidya S, Hippe DS. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol. 2015;38:913-921. [PMID: 25373795 DOI: 10.1007/s00270-014-1009-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
76 Kanata N, Yoshikawa T, Ohno Y, Kanda T, Uchida K, Izaki K, Fukumoto T, Ku Y, Itoh T, Kitajima K, Takahashi S, Sugimura K. HCC-to-liver contrast on arterial-dominant phase images of EOB-enhanced MRI: comparison with dynamic CT. Magnetic Resonance Imaging 2013;31:17-22. [DOI: 10.1016/j.mri.2012.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
77 Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24:965-973. [PMID: 23223331 DOI: 10.1093/annonc/mds605] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
78 Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. Eur J Radiol. 2013;82:e205-e211. [PMID: 23273822 DOI: 10.1016/j.ejrad.2012.12.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
79 Guo Y, Yaghmai V, Salem R, Lewandowski RJ, Nikolaidis P, Larson AC, Miller FH. Imaging tumor response following liver-directed intra-arterial therapy. Abdom Imaging. 2013;38:1286-1299. [PMID: 23807705 DOI: 10.1007/s00261-013-0017-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
80 Wang D, Gaba RC, Jin B, Lewandowski RJ, Riaz A, Memon K, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97. [PMID: 24678859 DOI: 10.1148/radiol.14131311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
81 Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708-718. [PMID: 22187634 DOI: 10.1148/radiol.11110282] [Cited by in Crossref: 186] [Cited by in F6Publishing: 178] [Article Influence: 16.9] [Reference Citation Analysis]
82 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:207-224. [PMID: 22941023 DOI: 10.1007/978-3-642-16037-0_14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
83 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
84 Hsu C, Po-Ching-Liang S, Hu FC, Cheng AL. Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. Liver Cancer. 2012;1:168-176. [PMID: 24159581 DOI: 10.1159/000343830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
85 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
86 Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol 2013;24:1147-53. [PMID: 23792126 DOI: 10.1016/j.jvir.2013.04.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
87 Alem Z, Murray TE, Egri C, Chung J, Liu D, Elsayes KM, Chang SD, Harris A. Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3596-614. [PMID: 33909092 DOI: 10.1007/s00261-021-03095-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Kallini JR, Miller FH, Gabr A, Salem R, Lewandowski RJ. Hepatic imaging following intra-arterial embolotherapy. Abdom Radiol (NY) 2016;41:600-16. [PMID: 26826088 DOI: 10.1007/s00261-016-0639-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
89 Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, Regnault H, Amaddeo G, Itti E, Luciani A, Kobeiter H, Tacher V. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44. [PMID: 33012693 DOI: 10.1016/j.diii.2020.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
90 Patel T, Harnois D. Assessment of response to therapy in hepatocellular carcinoma. Ann Med 2014;46:130-7. [PMID: 24716738 DOI: 10.3109/07853890.2014.891355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
91 Mahmud N, Hoteit MA, Goldberg DS. Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation. Liver Transpl 2020;26:977-88. [PMID: 32363720 DOI: 10.1002/lt.25787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
92 Salem R, Li D, Sommer N, Hernandez S, Verret W, Ding B, Lencioni R. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Med 2021;10:5437-47. [PMID: 34189869 DOI: 10.1002/cam4.4090] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, Janne d'Othée B, Padia SA, Salem R, Wang DS, Nikolic B, Brown DB; Society of Interventional Radiology Technology Assessment Committee. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol 2016;27:457-73. [PMID: 26851158 DOI: 10.1016/j.jvir.2015.12.752] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
94 Li Z, Bonekamp S, Halappa VG, Corona-Villalobos CP, Pawlik T, Bhagat N, Reyes D, Lai H, Geschwind JF, Kamel IR. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology. 2012;264:97-109. [PMID: 22627602 DOI: 10.1148/radiol.12112161] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
95 Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82:e212-e218. [PMID: 23332890 DOI: 10.1016/j.ejrad.2012.12.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
96 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 30.9] [Reference Citation Analysis]
97 Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2016;278:275-284. [PMID: 26131913 DOI: 10.1148/radiol.2015142951] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
98 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Kim BK, Kim KA, Kim M, Park JY, Kim DY, Ahn SH, Han K, Kim SU, Park M. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. Digestive and Liver Disease 2015;47:682-8. [DOI: 10.1016/j.dld.2015.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
100 Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer. Radiology 2015;274:320-34. [PMID: 25625741 DOI: 10.1148/radiol.14131925] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 12.6] [Reference Citation Analysis]
101 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
102 Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology. 2015;62:1111-1121. [PMID: 25999236 DOI: 10.1002/hep.27915] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
103 Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, Haydel B, Hoteit M, Levine MH, Lee DD, Taner CB, Verna EC, Halazun KJ, Abdelmessih R, Tevar AD, Humar A, Aucejo F, Chapman WC, Vachharajani N, Nguyen MH, Melcher ML, Nydam TL, Mobley C, Ghobrial RM, Amundsen B, Markmann JF, Langnas AN, Carney CA, Berumen J, Hemming AW, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Busuttil RW. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg. 2017;266:525-535. [PMID: 28654545 DOI: 10.1097/sla.0000000000002381] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 12.6] [Reference Citation Analysis]
104 Donati OF, Do RK, Hötker AM, Katz SS, Zheng J, Moskowitz CS, Beattie C, Brown KT. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. Eur Radiol 2015;25:2779-88. [PMID: 25850892 DOI: 10.1007/s00330-015-3677-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
105 Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Eur J Gastroenterol Hepatol 2013;25:620-7. [PMID: 23325276 DOI: 10.1097/MEG.0b013e32835ced13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
106 Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol 2017;209:277-88. [PMID: 28463538 DOI: 10.2214/AJR.17.18264] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 7.8] [Reference Citation Analysis]
107 Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? Cardiovasc Intervent Radiol. 2018;41:433-442. [PMID: 29086058 DOI: 10.1007/s00270-017-1829-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
108 Guibal A, Lefort T, Chardon L, Benslama N, Mulé S, Pilleul F, Lombard-Bohas C, Bridal L, Chayvialle JA, Lucidarme O. Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation. Eur Radiol. 2013;23:805-815. [PMID: 23001579 DOI: 10.1007/s00330-012-2646-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
109 Chao M, Wu H, Jin K, Li B, Wu J, Zhang G, Yang G, Hu X. A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis. Elife. 2016;5:e15691. [PMID: 27481188 DOI: 10.7554/elife.15691] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
110 Parma J, Pavlick A, Schiff R, Osborne CK, Chang JC, Rimawi M, Trivedi MV. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy 2013;33:1126-9. [PMID: 23744830 DOI: 10.1002/phar.1308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Corona-Villalobos CP, Zhang Y, Zhang WD, Kamel IR. Magnetic resonance imaging of the liver after loco-regional and systemic therapy. Magn Reson Imaging Clin N Am 2014;22:353-72. [PMID: 25086934 DOI: 10.1016/j.mric.2014.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
112 Ali R, Yang Y, Antkowiak M, Gabr A, Mora R, Abouchaleh N, Al Asadi A, Kulik L, Ganger D, Abecassis M, Kataraya N, Mulcahy M, Benson A, Mahalingam D, Thornburg B, Mouli S, Lewandowski RJ, Salem R, Riaz A. Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. Cardiovasc Intervent Radiol 2019;42:700-11. [DOI: 10.1007/s00270-019-02191-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 16.9] [Reference Citation Analysis]
114 Epstein AS, O'Reilly EM, Lowery M, Shamseddine A, Shia J, Temraz S, Al-Olayan A, Naghy M, Kelsen D, Shah MA, Abou-Alfa GK. A woman with remotely treated pancreas cancer and new abdominal pain: a discussion of evaluation and management. J Gastrointest Cancer 2011;42:236-40. [PMID: 21132573 DOI: 10.1007/s12029-010-9234-0] [Reference Citation Analysis]
115 Lewis H, Ghasabeh M, Khoshpouri P, Kamel I, Pawlik T. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology 2017;26:411-22. [DOI: 10.1016/j.suronc.2017.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
116 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
117 Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 2012;265:115-23. [PMID: 22891361 DOI: 10.1148/radiol.12112264] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
118 Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151:1155-1163.e2. [PMID: 27575820 DOI: 10.1053/j.gastro.2016.08.029] [Cited by in Crossref: 243] [Cited by in F6Publishing: 209] [Article Influence: 40.5] [Reference Citation Analysis]
119 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:401-20. [DOI: 10.1016/j.cld.2015.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
120 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 108] [Article Influence: 10.3] [Reference Citation Analysis]
121 Shi HY, Wang SN, Wang SC, Chuang SC, Chen CM, Lee KT. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors. J Surg Oncol 2014;109:487-93. [PMID: 24293372 DOI: 10.1002/jso.23521] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
122 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
123 Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015;8:609. [PMID: 26502722 DOI: 10.1186/s13104-015-1565-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
124 Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, Van Vlierberghe H, Defreyne L. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 2011;38:2117-24. [DOI: 10.1007/s00259-011-1881-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
125 Kim DG, Lee JG, Joo DJ, Kim SI, Kim MS. Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation. Sci Rep 2019;9:10386. [PMID: 31316165 DOI: 10.1038/s41598-019-46871-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015;10:e0133488. [PMID: 26230853 DOI: 10.1371/journal.pone.0133488] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
127 Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han K, Baek S, Kim HS, Kim SU, Park MS. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. Liver Int 2018;38:1655-63. [DOI: 10.1111/liv.13731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
128 Kim MN, Kim BK, Han K, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2014;9:335-48. [DOI: 10.1586/17474124.2015.959929] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
129 Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee., Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-78. [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 13.5] [Reference Citation Analysis]
130 Ye Z, Deng Z, Jiang S, Wang T, Liu L, Jiang K, Zhang Y. Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy. Cardiovasc Intervent Radiol 2021;44:1394-402. [PMID: 33948697 DOI: 10.1007/s00270-021-02846-w] [Reference Citation Analysis]
131 Miller FH, Lopes Vendrami C, Gabr A, Horowitz JM, Kelahan LC, Riaz A, Salem R, Lewandowski RJ. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021;41:1802-18. [PMID: 34559587 DOI: 10.1148/rg.2021210014] [Reference Citation Analysis]
132 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
133 Yang JF, Lo CH, Huang WY. Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? J Clin Oncol 2016;34:2797. [PMID: 27325860 DOI: 10.1200/JCO.2016.66.4458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
134 Hyun D, Shin SW, Cho SK, Park KB, Park HS, Choo SW, Do YS, Choo I, Shin J, Lim S. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol 2015;56:1437-45. [DOI: 10.1177/0284185114560937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
135 Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, Kallini J, Salem R, Lewandowski RJ. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2018;41:1557-65. [PMID: 29948005 DOI: 10.1007/s00270-018-2008-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
136 Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181-1187. [PMID: 23395691 DOI: 10.1016/j.jhep.2013.01.039] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 9.1] [Reference Citation Analysis]